Market revenue in 2023 | USD 8.9 million |
Market revenue in 2030 | USD 13.0 million |
Growth rate | 5.6% (CAGR from 2023 to 2030) |
Largest segment | Cardiopulmonary perfusion system |
Fastest growing segment | Cardiopulmonary Perfusion System |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cardiopulmonary Perfusion System, Cell Perfusion System, Ex-Vivo Organ Perfusion System |
Key market players worldwide | Getinge AB ADR, Medtronic PLC, LivaNova PLC, Terumo Corp, Nipro Corp, Fresenius Medical Care AG, Repligen Corp, Spectrum Brands Holdings Inc, Merck KGaA, Xvivo Perfusion AB |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to perfusion systems market will help companies and investors design strategic landscapes.
Cardiopulmonary perfusion system was the largest segment with a revenue share of 42.7% in 2023. Horizon Databook has segmented the UAE perfusion systems market based on cardiopulmonary perfusion system, cell perfusion system, ex-vivo organ perfusion system covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of chronic health conditions and the growing adoption of advanced medical technologies are the major driving factors for the UAE perfusion systems market. According to a report by the International Diabetes Federation, in 2021, the prevalence of diabetes in UAE adults was 12.3% (990,900 cases).
In addition, according to a new study commissioned by Cleveland Clinic Abu Dhabi, more than half of UAE citizens are affected with heart disease during their lifetime. The poll of more than 1,000 UAE residents indicated that the percentage of respondents directly affected with heart disease was 55%, either by their diagnosis (12%), the diagnosis of a close friend or family member (53%), or both.
In the UAE, cardiovascular disease is the main cause of mortality, with patients frequently experiencing symptoms a decade sooner than their counterparts in other industrialized countries. This demand is compelling manufacturers to introduce innovative products, driving the UAE market.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE perfusion systems market , including forecasts for subscribers. This country databook contains high-level insights into UAE perfusion systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account